世界の骨髄性プロトポルフィリン症（EPP）治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Erythropoietic Protoporphyria (EPP) Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4205 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、骨髄性プロトポルフィリン症（EPP）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ホルモン療法、補助療法、光線療法）、用途別市場規模（病院薬局、ドラッグストア、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・骨髄性プロトポルフィリン症（EPP）治療の市場動向 ・企業の競争状況、市場シェア ・骨髄性プロトポルフィリン症（EPP）治療の種類別市場規模と予測2016-2027（ホルモン療法、補助療法、光線療法） ・骨髄性プロトポルフィリン症（EPP）治療の用途別市場規模と予測2016-2027（病院薬局、ドラッグストア、小売薬局、オンライン薬局） ・骨髄性プロトポルフィリン症（EPP）治療の北米市場規模2016-2027（アメリカ、カナダ） ・骨髄性プロトポルフィリン症（EPP）治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・骨髄性プロトポルフィリン症（EPP）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・骨髄性プロトポルフィリン症（EPP）治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・骨髄性プロトポルフィリン症（EPP）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Clinuvel Pharmaceuticals ALS、L'Oréal S.A.、Tishcon Corp.、In-Life Co.、Pfizer Inc.、Fenton Pharmaceuticals Ltd.、Teva Pharmaceuticals、Mylan N.V.、Johnson and Johnson） ・結論

Erythropoietic protoporphyria (EPP) is a rare inherited metabolic disorder caused by a deficiency of the enzyme ferrochelatase (FECH), which results from changes (mutations) in the FECH gene. Due to abnormally low levels of this enzyme, excessive amounts of protoporphyrin accumulate in the bone marrow, blood plasma, and red blood cells. Some patients with symptoms of EPP have a genetic change in a different gene called ALAS2. When a patient has a genetic change in this gene, the condition is referred to as X-linked protoporphyria (XLP).

Market Analysis and Insights: Global Erythropoietic Protoporphyria (EPP) Treatment Market
The global Erythropoietic Protoporphyria (EPP) Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Erythropoietic Protoporphyria (EPP) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Erythropoietic Protoporphyria (EPP) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Erythropoietic Protoporphyria (EPP) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Erythropoietic Protoporphyria (EPP) Treatment market.

Global Erythropoietic Protoporphyria (EPP) Treatment Scope and Market Size
Erythropoietic Protoporphyria (EPP) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Erythropoietic Protoporphyria (EPP) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Hormonal Therapy
Adjunctive Therapies
Phototherapy

Segment by Application
Hospital Pharmacies
Drug Stores
Retail Pharmacies
Online Pharmacies

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Clinuvel Pharmaceuticals ALS
L’Oréal S.A.
Tishcon Corp.
In-Life Co.
Pfizer Inc.
Fenton Pharmaceuticals Ltd.
Teva Pharmaceuticals
Mylan N.V.
Johnson and Johnson

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Erythropoietic Protoporphyria (EPP) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Hormonal Therapy
1.2.3 Adjunctive Therapies
1.2.4 Phototherapy
1.3 Market by Application
1.3.1 Global Erythropoietic Protoporphyria (EPP) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Drug Stores
1.3.4 Retail Pharmacies
1.3.5 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Erythropoietic Protoporphyria (EPP) Treatment Market Perspective (2016-2027)
2.2 Erythropoietic Protoporphyria (EPP) Treatment Growth Trends by Regions
2.2.1 Erythropoietic Protoporphyria (EPP) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Erythropoietic Protoporphyria (EPP) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Erythropoietic Protoporphyria (EPP) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Erythropoietic Protoporphyria (EPP) Treatment Industry Dynamic
2.3.1 Erythropoietic Protoporphyria (EPP) Treatment Market Trends
2.3.2 Erythropoietic Protoporphyria (EPP) Treatment Market Drivers
2.3.3 Erythropoietic Protoporphyria (EPP) Treatment Market Challenges
2.3.4 Erythropoietic Protoporphyria (EPP) Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Erythropoietic Protoporphyria (EPP) Treatment Players by Revenue
3.1.1 Global Top Erythropoietic Protoporphyria (EPP) Treatment Players by Revenue (2016-2021)
3.1.2 Global Erythropoietic Protoporphyria (EPP) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Erythropoietic Protoporphyria (EPP) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Erythropoietic Protoporphyria (EPP) Treatment Revenue
3.4 Global Erythropoietic Protoporphyria (EPP) Treatment Market Concentration Ratio
3.4.1 Global Erythropoietic Protoporphyria (EPP) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Erythropoietic Protoporphyria (EPP) Treatment Revenue in 2020
3.5 Erythropoietic Protoporphyria (EPP) Treatment Key Players Head office and Area Served
3.6 Key Players Erythropoietic Protoporphyria (EPP) Treatment Product Solution and Service
3.7 Date of Enter into Erythropoietic Protoporphyria (EPP) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Erythropoietic Protoporphyria (EPP) Treatment Breakdown Data by Type
4.1 Global Erythropoietic Protoporphyria (EPP) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Erythropoietic Protoporphyria (EPP) Treatment Forecasted Market Size by Type (2022-2027)

5 Erythropoietic Protoporphyria (EPP) Treatment Breakdown Data by Application
5.1 Global Erythropoietic Protoporphyria (EPP) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Erythropoietic Protoporphyria (EPP) Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size (2016-2027)
6.2 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type
6.2.1 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2021)
6.2.2 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2022-2027)
6.2.3 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2027)
6.3 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application
6.3.1 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2021)
6.3.2 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2022-2027)
6.3.3 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2027)
6.4 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country
6.4.1 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2016-2021)
6.4.2 North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size (2016-2027)
7.2 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type
7.2.1 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2027)
7.3 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application
7.3.1 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2027)
7.4 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country
7.4.1 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type
8.2.1 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application
8.3.1 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Region
8.4.1 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size (2016-2027)
9.2 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type
9.2.1 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2027)
9.3 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application
9.3.1 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2027)
9.4 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country
9.4.1 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type
10.2.1 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application
10.3.1 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country
10.4.1 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Clinuvel Pharmaceuticals ALS
11.1.1 Clinuvel Pharmaceuticals ALS Company Details
11.1.2 Clinuvel Pharmaceuticals ALS Business Overview
11.1.3 Clinuvel Pharmaceuticals ALS Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.1.4 Clinuvel Pharmaceuticals ALS Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.1.5 Clinuvel Pharmaceuticals ALS Recent Development
11.2 L’Oréal S.A.
11.2.1 L’Oréal S.A. Company Details
11.2.2 L’Oréal S.A. Business Overview
11.2.3 L’Oréal S.A. Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.2.4 L’Oréal S.A. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.2.5 L’Oréal S.A. Recent Development
11.3 Tishcon Corp.
11.3.1 Tishcon Corp. Company Details
11.3.2 Tishcon Corp. Business Overview
11.3.3 Tishcon Corp. Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.3.4 Tishcon Corp. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.3.5 Tishcon Corp. Recent Development
11.4 In-Life Co.
11.4.1 In-Life Co. Company Details
11.4.2 In-Life Co. Business Overview
11.4.3 In-Life Co. Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.4.4 In-Life Co. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.4.5 In-Life Co. Recent Development
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Company Details
11.5.2 Pfizer Inc. Business Overview
11.5.3 Pfizer Inc. Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.5.4 Pfizer Inc. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.5.5 Pfizer Inc. Recent Development
11.6 Fenton Pharmaceuticals Ltd.
11.6.1 Fenton Pharmaceuticals Ltd. Company Details
11.6.2 Fenton Pharmaceuticals Ltd. Business Overview
11.6.3 Fenton Pharmaceuticals Ltd. Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.6.4 Fenton Pharmaceuticals Ltd. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.6.5 Fenton Pharmaceuticals Ltd. Recent Development
11.7 Teva Pharmaceuticals
11.7.1 Teva Pharmaceuticals Company Details
11.7.2 Teva Pharmaceuticals Business Overview
11.7.3 Teva Pharmaceuticals Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.7.4 Teva Pharmaceuticals Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.7.5 Teva Pharmaceuticals Recent Development
11.8 Mylan N.V.
11.8.1 Mylan N.V. Company Details
11.8.2 Mylan N.V. Business Overview
11.8.3 Mylan N.V. Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.8.4 Mylan N.V. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.8.5 Mylan N.V. Recent Development
11.9 Johnson and Johnson
11.9.1 Johnson and Johnson Company Details
11.9.2 Johnson and Johnson Business Overview
11.9.3 Johnson and Johnson Erythropoietic Protoporphyria (EPP) Treatment Introduction
11.9.4 Johnson and Johnson Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
11.9.5 Johnson and Johnson Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Erythropoietic Protoporphyria (EPP) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Hormonal Therapy
Table 3. Key Players of Adjunctive Therapies
Table 4. Key Players of Phototherapy
Table 5. Global Erythropoietic Protoporphyria (EPP) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Erythropoietic Protoporphyria (EPP) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Erythropoietic Protoporphyria (EPP) Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Erythropoietic Protoporphyria (EPP) Treatment Market Share by Regions (2016-2021)
Table 9. Global Erythropoietic Protoporphyria (EPP) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Erythropoietic Protoporphyria (EPP) Treatment Market Share by Regions (2022-2027)
Table 11. Erythropoietic Protoporphyria (EPP) Treatment Market Trends
Table 12. Erythropoietic Protoporphyria (EPP) Treatment Market Drivers
Table 13. Erythropoietic Protoporphyria (EPP) Treatment Market Challenges
Table 14. Erythropoietic Protoporphyria (EPP) Treatment Market Restraints
Table 15. Global Erythropoietic Protoporphyria (EPP) Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Erythropoietic Protoporphyria (EPP) Treatment Market Share by Players (2016-2021)
Table 17. Global Top Erythropoietic Protoporphyria (EPP) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Erythropoietic Protoporphyria (EPP) Treatment as of 2020)
Table 18. Ranking of Global Top Erythropoietic Protoporphyria (EPP) Treatment Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Erythropoietic Protoporphyria (EPP) Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Erythropoietic Protoporphyria (EPP) Treatment Product Solution and Service
Table 22. Date of Enter into Erythropoietic Protoporphyria (EPP) Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Erythropoietic Protoporphyria (EPP) Treatment Revenue Market Share by Type (2016-2021)
Table 26. Global Erythropoietic Protoporphyria (EPP) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Erythropoietic Protoporphyria (EPP) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Erythropoietic Protoporphyria (EPP) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Erythropoietic Protoporphyria (EPP) Treatment Revenue Market Share by Application (2016-2021)
Table 30. Global Erythropoietic Protoporphyria (EPP) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Erythropoietic Protoporphyria (EPP) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 62. Clinuvel Pharmaceuticals ALS Company Details
Table 63. Clinuvel Pharmaceuticals ALS Business Overview
Table 64. Clinuvel Pharmaceuticals ALS Erythropoietic Protoporphyria (EPP) Treatment Product
Table 65. Clinuvel Pharmaceuticals ALS Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021) & (US$ Million)
Table 66. Clinuvel Pharmaceuticals ALS Recent Development
Table 67. L'Oréal S.A. Company Details
Table 68. L'Oréal S.A. Business Overview
Table 69. L'Oréal S.A. Erythropoietic Protoporphyria (EPP) Treatment Product
Table 70. L'Oréal S.A. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021) & (US$ Million)
Table 71. L'Oréal S.A. Recent Development
Table 72. Tishcon Corp. Company Details
Table 73. Tishcon Corp. Business Overview
Table 74. Tishcon Corp. Erythropoietic Protoporphyria (EPP) Treatment Product
Table 75. Tishcon Corp. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021) & (US$ Million)
Table 76. Tishcon Corp. Recent Development
Table 77. In-Life Co. Company Details
Table 78. In-Life Co. Business Overview
Table 79. In-Life Co. Erythropoietic Protoporphyria (EPP) Treatment Product
Table 80. In-Life Co. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021) & (US$ Million)
Table 81. In-Life Co. Recent Development
Table 82. Pfizer Inc. Company Details
Table 83. Pfizer Inc. Business Overview
Table 84. Pfizer Inc. Erythropoietic Protoporphyria (EPP) Treatment Product
Table 85. Pfizer Inc. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021) & (US$ Million)
Table 86. Pfizer Inc. Recent Development
Table 87. Fenton Pharmaceuticals Ltd. Company Details
Table 88. Fenton Pharmaceuticals Ltd. Business Overview
Table 89. Fenton Pharmaceuticals Ltd. Erythropoietic Protoporphyria (EPP) Treatment Product
Table 90. Fenton Pharmaceuticals Ltd. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021) & (US$ Million)
Table 91. Fenton Pharmaceuticals Ltd. Recent Development
Table 92. Teva Pharmaceuticals Company Details
Table 93. Teva Pharmaceuticals Business Overview
Table 94. Teva Pharmaceuticals Erythropoietic Protoporphyria (EPP) Treatment Product
Table 95. Teva Pharmaceuticals Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021) & (US$ Million)
Table 96. Teva Pharmaceuticals Recent Development
Table 97. Mylan N.V. Company Details
Table 98. Mylan N.V. Business Overview
Table 99. Mylan N.V. Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021) & (US$ Million)
Table 100. Mylan N.V. Recent Development
Table 101. Johnson and Johnson Company Details
Table 102. Johnson and Johnson Business Overview
Table 103. Johnson and Johnson Erythropoietic Protoporphyria (EPP) Treatment Product
Table 104. Johnson and Johnson Revenue in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021) & (US$ Million)
Table 105. Johnson and Johnson Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Erythropoietic Protoporphyria (EPP) Treatment Market Share by Type: 2020 VS 2027
Figure 2. Hormonal Therapy Features
Figure 3. Adjunctive Therapies Features
Figure 4. Phototherapy Features
Figure 5. Global Erythropoietic Protoporphyria (EPP) Treatment Market Share by Application: 2020 VS 2027
Figure 6. Hospital Pharmacies Case Studies
Figure 7. Drug Stores Case Studies
Figure 8. Retail Pharmacies Case Studies
Figure 9. Online Pharmacies Case Studies
Figure 10. Erythropoietic Protoporphyria (EPP) Treatment Report Years Considered
Figure 11. Global Erythropoietic Protoporphyria (EPP) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Erythropoietic Protoporphyria (EPP) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Erythropoietic Protoporphyria (EPP) Treatment Market Share by Regions: 2020 VS 2027
Figure 14. Global Erythropoietic Protoporphyria (EPP) Treatment Market Share by Regions (2022-2027)
Figure 15. Global Erythropoietic Protoporphyria (EPP) Treatment Market Share by Players in 2020
Figure 16. Global Top Erythropoietic Protoporphyria (EPP) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Erythropoietic Protoporphyria (EPP) Treatment as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Erythropoietic Protoporphyria (EPP) Treatment Revenue in 2020
Figure 18. Global Erythropoietic Protoporphyria (EPP) Treatment Revenue Market Share by Type (2016-2021)
Figure 19. Global Erythropoietic Protoporphyria (EPP) Treatment Revenue Market Share by Type (2022-2027)
Figure 20. North America Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Erythropoietic Protoporphyria (EPP) Treatment Market Share by Type (2016-2027)
Figure 22. North America Erythropoietic Protoporphyria (EPP) Treatment Market Share by Application (2016-2027)
Figure 23. North America Erythropoietic Protoporphyria (EPP) Treatment Market Share by Country (2016-2027)
Figure 24. United States Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Erythropoietic Protoporphyria (EPP) Treatment Market Share by Type (2016-2027)
Figure 28. Europe Erythropoietic Protoporphyria (EPP) Treatment Market Share by Application (2016-2027)
Figure 29. Europe Erythropoietic Protoporphyria (EPP) Treatment Market Share by Country (2016-2027)
Figure 30. Germany Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Erythropoietic Protoporphyria (EPP) Treatment Market Share by Region (2016-2027)
Figure 40. China Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Share by Type (2016-2027)
Figure 48. Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Share by Application (2016-2027)
Figure 49. Latin America Erythropoietic Protoporphyria (EPP) Treatment Market Share by Country (2016-2027)
Figure 50. Mexico Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Erythropoietic Protoporphyria (EPP) Treatment Market Share by Country (2016-2027)
Figure 56. Turkey Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Erythropoietic Protoporphyria (EPP) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Clinuvel Pharmaceuticals ALS Revenue Growth Rate in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
Figure 60. L'Oréal S.A. Revenue Growth Rate in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
Figure 61. Tishcon Corp. Revenue Growth Rate in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
Figure 62. In-Life Co. Revenue Growth Rate in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
Figure 63. Pfizer Inc. Revenue Growth Rate in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
Figure 64. Fenton Pharmaceuticals Ltd. Revenue Growth Rate in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
Figure 65. Teva Pharmaceuticals Revenue Growth Rate in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
Figure 66. Mylan N.V. Revenue Growth Rate in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
Figure 67. Johnson and Johnson Revenue Growth Rate in Erythropoietic Protoporphyria (EPP) Treatment Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

---